Tib neeg eml4-alk fusion gene mution

Cov khoom siv no tau siv los tsim nyog soj ntsuam 12 lub zog ntawm eml4-alk fusion gene hauv tib neeg cov neeg mob cell rog me me cell mob hauv vitro. Cov kev sim ntsuas yog rau kev kuaj mob siv xwb thiab yuav tsum tsis txhob siv los ua ib qho kev kho mob rau tus kheej. Cov kws kho mob yuav tsum txiav txim siab rau cov txiaj ntsig kev kuaj mob raws li cov neeg mob, kev tshawb fawb tshuaj, kho yeeb yaj kiab kho, thiab lwm yam chaw kuaj kuaj. Mob ntsws mob ntsws yog feem ntau cov qog nqaij hlav loj tshaj plaws thoob ntiaj teb, thiab 805% ntawm cov rooj plaub tsis yog mob cancer mob cancer me me (NSCLC). Gene Fusion ntawm Echinoderm MicroTOr-zoo li 4 (EML4) thiab Alk) yog cov khoom siv ntawm Chromosome 2 thiab tau sib cais los ntawm kwv yees li 12.7 lab lab khub. Tsawg kawg 20 fusion variants tau pom, ntawm 12 qhov kev sib cav sib txawv hauv cov lus 1 (E13; A20) thiab 3b; A20), Accounting rau txog 33% thiab 29% ntawm cov neeg mob nrog eml4-alk fusion gene NSCLC, feem. Alk inhibitors sawv cev los ntawm Crizotinib yog cov tshuaj uas muaj cov tshuaj tiv thaiv me me tau tsim rau Alk Gene kev hloov pauv. Los ntawm inhibiting qhov kev ua ntawm Alk Tyrosine Kinase cheeb tsam, thaiv nws txoj kev loj hlob ntawm cov qog nqaij hlav, kom ua tiav cov phiaj kev kho mob rau hlav hlav. Cov kev tshawb fawb soj ntsuam tau qhia tias Crizotinib muaj tus nqi ntau dua 61% hauv cov neeg mob eml4-alk fusion hloov, thaum nws yuav luag tsis cuam tshuam rau cov tsiaj qus. Yog li ntawd, kev tshawb pom ntawm eml4-alk fusion strate yog lub hauv paus thiab hauv paus rau kev pab ntawm kev siv cov khoom crizotinib.